DDW 2026 at a glance
DDW 2026 in Chicago highlights emerging developments in gastroenterology, from inflammatory bowel disease and advanced endoscopy to gastrointestinal oncology, hepatology, microbiome research and metabolic care.
Artificial intelligence and machine learning are also key themes, with applications spanning diagnostic imaging, endoscopy quality, treatment response prediction and clinical decision-making.
📅 Build your schedule around the sessions that matter most.
📥 Download the DDW 2026_Preview_by_LucidQuest
DDW 2026: Key Gastroenterology Developments to Watch
Inflammatory Bowel Disease (IBD)
IL-23 trials will reinforce dominance, while TL1A, biomarkers, microbiome, and de-escalation studies refine targeting.
Endoscopy and Advanced Therapeutics
CAD colonoscopy, ACOSER, RECOVER, LAMS, and ESG studies will advance detection, safety, and minimally invasive care.
Pancreatic and Biliary Diseases
CERES-BILAT, CHOICE, RFA, radionuclide therapy, and stents will reshape ERCP and malignancy management.
GI Oncology and Premalignant Disease
ESOPEC, BAMBI cfDNA, Barrett’s data, anti-PD-1 studies, and panitumumab meta-analysis will refine detection and therapy.
Hepatology and Liver Disease
MASLD trials and large cirrhosis cohorts will clarify treatment hierarchy, outcomes, screening gaps, and elastography programs.
Functional GI Disorders and Motility
FMT-FD, TRIUMPH IBS, gut–brain RCTs, Low-FODMAP, and POEM trials will refine symptom control.
Microbiome and Translational Science
CDI-SCOPE, MIRO, immune modulation, multi-omics, and microbial oncology studies will link microbiota to outcomes.
Obesity, Nutrition and Surgical Innovation
ESG, GLP-1s, mucosal ablation, combination therapy, and bariatric outcomes will redefine metabolic care.
Artificial Intelligence and Machine Learning at DDW 2026
Pancreatic AI Imaging
EfficientNet and ResNet models are set to expand CT/MRI detection, with one ResNet152 study reporting >99% accuracy.
Endoscopy Quality Automation
AI models are expected to assess bowel prep, withdrawal time, adenoma yield, and upper GI quality indicators.
IBD Precision Modeling
ML and multi-omics are set to predict onset, pediatric progression, postoperative recurrence, and treatment response.
Hepatology Risk Prediction
AI models are expected to refine cirrhosis survival, SBP exclusion, alcoholic hepatitis prognosis, and HCC selection.
LLMs in Clinical Decision-Making
ChatGPT, OpenEvidence, and multi-agent systems are set to be tested against guidelines and surveillance tasks.
Microbiome and Multi-Omics AI
ML is expected to integrate microbial, diet, proteomic, transcriptomic, and exosomal data for risk and matching.
Download LucidQuest’s DDW 2026 Preview Report
Download our DDW 2026 preview report for deeper analysis of emerging gastroenterology therapies, clinical developments, microbiome research, diagnostic innovation and AI applications in digestive health.
📅 Build your schedule around the topics that matter most.
📥 Download the DDW 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
